What is a stock summary page? Click here for an overview.
Business Description
VYNE Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US5868581027
Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 621.37 | |||||
| Equity-to-Asset | 0.78 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -15.31 | |||||
| Beneish M-Score | -3.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -66.7 | |||||
| 3-Year EBITDA Growth Rate | 57.8 | |||||
| 3-Year EPS without NRI Growth Rate | 60.8 | |||||
| 3-Year FCF Growth Rate | 65.6 | |||||
| 3-Year Book Growth Rate | -40.1 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.68 | |||||
| 9-Day RSI | 27.65 | |||||
| 14-Day RSI | 29.57 | |||||
| 3-1 Month Momentum % | -21.05 | |||||
| 6-1 Month Momentum % | 35.64 | |||||
| 12-1 Month Momentum % | -9.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.35 | |||||
| Quick Ratio | 4.35 | |||||
| Cash Ratio | 4.15 | |||||
| Days Sales Outstanding | 182.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -70.8 | |||||
| Shareholder Yield % | 0.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -8709.98 | |||||
| Net Margin % | -7950.9 | |||||
| FCF Margin % | -6780.84 | |||||
| ROE % | -54.93 | |||||
| ROA % | -47.52 | |||||
| ROIC % | -1041.71 | |||||
| 3-Year ROIIC % | 116.75 | |||||
| ROC (Joel Greenblatt) % | -25194.57 | |||||
| ROCE % | -59.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 142.5 | |||||
| PB Ratio | 0.49 | |||||
| Price-to-Tangible-Book | 0.49 | |||||
| EV-to-EBIT | 0.8 | |||||
| EV-to-Forward-EBIT | -0.1 | |||||
| EV-to-EBITDA | 0.8 | |||||
| EV-to-Forward-EBITDA | -0.1 | |||||
| EV-to-Revenue | -69.76 | |||||
| EV-to-Forward-Revenue | 0.19 | |||||
| EV-to-FCF | 1.03 | |||||
| Price-to-GF-Value | 5.52 | |||||
| Price-to-Net-Current-Asset-Value | 0.51 | |||||
| Price-to-Net-Cash | 0.54 | |||||
| Earnings Yield (Greenblatt) % | 125 | |||||
| FCF Yield % | -130.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VYNE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VYNE Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.501 | ||
| EPS (TTM) ($) | -0.94 | ||
| Beta | 2.09 | ||
| 3-Year Sharpe Ratio | -0.07 | ||
| 3-Year Sortino Ratio | -0.12 | ||
| Volatility % | 76.45 | ||
| 14-Day RSI | 29.57 | ||
| 14-Day ATR ($) | 0.195151 | ||
| 20-Day SMA ($) | 2.0445 | ||
| 12-1 Month Momentum % | -9.89 | ||
| 52-Week Range ($) | 1.57 - 4.3 | ||
| Shares Outstanding (Mil) | 15.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VYNE Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VYNE Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
VYNE Therapeutics Inc Frequently Asked Questions
What is VYNE Therapeutics Inc(VYNE)'s stock price today?
The current price of VYNE is $1.71. The 52 week high of VYNE is $4.30 and 52 week low is $1.57.
When is next earnings date of VYNE Therapeutics Inc(VYNE)?
The next earnings date of VYNE Therapeutics Inc(VYNE) is 2025-05-09 Est..
Does VYNE Therapeutics Inc(VYNE) pay dividends? If so, how much?
VYNE Therapeutics Inc(VYNE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers